Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012, Article ID 707156, 11 pages
http://dx.doi.org/10.1155/2012/707156
Review Article

To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients

1Department of Surgery, St. Luke’s University Health Network, 801 Ostrum Street, Bethlehem, PA 18015, USA
2Division of Surgical Oncology, Cancer Care Associates, St. Luke’s University Health Network, 1872 Riverside Circle, Easton, PA 18045, USA

Received 11 July 2012; Revised 14 September 2012; Accepted 18 September 2012

Academic Editor: A. J. M. Balm

Copyright © 2012 Marilee Carballo and Roderick M. Quiros. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. D. S. Cooper, G. M. Doherty, B. R. Haugen et al., “Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 19, no. 11, pp. 1167–1214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. H. O. Mäenpää, J. Heikkonen, L. Vaalavirta, M. Tenhunen, and H. Joensuu, “Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study,” PLoS ONE, vol. 3, no. 4, Article ID e1885, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Yoo, S. Ajmal, S. Gowda, J. MacHan, J. Monchik, and P. Mazzaglia, “Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer,” World Journal of Surgery, vol. 36, no. 6, pp. 1255–1261, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. E. L. Mazzaferri and S. M. Jhiang, “Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer,” American Journal of Medicine, vol. 97, no. 5, pp. 418–428, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. M. J. Schlumberger, “Papillary and follicular thyroid carcinoma,” New England Journal of Medicine, vol. 338, no. 5, pp. 297–306, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Tubiana, M. Schlumberger, and P. Rougier, “Long-term results and prognostic factors in patients with differentiated thyroid carcinoma,” Cancer, vol. 55, no. 4, pp. 794–804, 1985. View at Google Scholar · View at Scopus
  8. R. M. Hirosawa, M. Marivo, M. Luengo Jde et al., “Does radioiodine therapy in patients with differentiated thyroid cancer increase the frequency of another malignant neoplasm?” ISRN Oncology, vol. 2011, Article ID 708343, 5 pages, 2011. View at Publisher · View at Google Scholar
  9. D. H. Y. Shen, R. T. Kloos, E. L. Mazzaferri, and S. M. Jhiang, “Sodium iodide symporter in health and disease,” Thyroid, vol. 11, no. 5, pp. 415–425, 2001. View at Google Scholar · View at Scopus
  10. A. De La Vieja, O. Dohan, O. Levy, and N. Carrasco, “Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology,” Physiological Reviews, vol. 80, no. 3, pp. 1083–1105, 2000. View at Google Scholar · View at Scopus
  11. E. B. Silberstein, “Radioiodine: the classic theranostic agent,” Seminars in Nuclear Medicine, vol. 42, no. 3, pp. 164–170, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. U. Mallick, C. Harmer, B. Yap et al., “Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer,” New England Journal of Medicine, vol. 366, no. 18, pp. 1674–1685, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. E. B. Silberstein, “Comparison of outcomes after 123I versus 131I preablation imaging before radioiodine ablation in differentiated thyroid carcinoma,” Journal of Nuclear Medicine, vol. 48, no. 7, pp. 1043–1046, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Ali, C. Sebastian, R. R. Foley et al., “The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy,” Nuclear Medicine Communications, vol. 27, no. 2, pp. 165–169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. J. Mandel, L. K. Shankar, F. Benard, A. Yamamoto, and A. Alavi, “Superiority of Iodine-123 Compared with Iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer,” Clinical Nuclear Medicine, vol. 26, no. 1, pp. 6–9, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Yaakob, L. Gordon, K. M. Spicer, and S. J. Nitke, “The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases,” Journal of Nuclear Medicine Technology, vol. 27, no. 4, pp. 279–281, 1999. View at Google Scholar · View at Scopus
  17. W. Brenner, “Is thyroid stunning a real phenomenon or just fiction?” Journal of Nuclear Medicine, vol. 43, no. 6, pp. 835–836, 2002. View at Google Scholar · View at Scopus
  18. W. Lees, R. Mansberg, J. Roberts, J. Towson, E. Chua, and J. Turtle, “The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I,” European Journal of Nuclear Medicine, vol. 29, no. 11, pp. 1421–1427, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. J. P. Muratet, A. Daver, J. F. Minier, and F. Larra, “Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma,” Journal of Nuclear Medicine, vol. 39, no. 9, pp. 1546–1550, 1998. View at Google Scholar · View at Scopus
  20. F. Pacini, L. Agate, R. Elisei et al., “Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131I whole body scan: comparison of patients treated with high 131I activities versus untreated patients,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 9, pp. 4092–4097, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. M. W. Ashcraft and A. J. Van Herle, “The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer,” American Journal of Medicine, vol. 71, no. 5, pp. 806–814, 1981. View at Google Scholar · View at Scopus
  22. J. D. Pineda, T. Lee, K. Ain, J. C. Reynolds, and J. Robbins, “Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan,” Journal of Clinical Endocrinology and Metabolism, vol. 80, no. 5, pp. 1488–1492, 1995. View at Google Scholar · View at Scopus
  23. M. Schlumberger, O. Arcangioli, J. D. Piekarski, M. Tubiana, and C. Parmentier, “Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-rays,” Journal of Nuclear Medicine, vol. 29, no. 11, pp. 1790–1794, 1988. View at Google Scholar · View at Scopus
  24. M. J. Dong, Z. F. Liu, K. Zhao et al., “Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis,” Nuclear Medicine Communications, vol. 30, no. 8, pp. 639–650, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Ma, J. Xie, Y. Lou, Y. Gao, S. Zuo, and X. Wang, “The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis,” European Journal of Endocrinology, vol. 163, no. 2, pp. 177–183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. W. J. Simpson, T. Panzarella, J. S. Carruthers, M. K. Gospodarowicz, and S. B. Sutcliffe, “Papillary and follicular thyroid cancer: impact of treatment in 1578 patients,” International Journal of Radiation Oncology Biology Physics, vol. 14, no. 6, pp. 1063–1075, 1988. View at Google Scholar · View at Scopus
  27. H. M. Park, “Stunned thyroid after high-dose I-131 imaging,” Clinical Nuclear Medicine, vol. 17, no. 6, pp. 501–502, 1992. View at Google Scholar · View at Scopus
  28. S. I. Sherman, E. T. Tielens, S. Sostre, M. D. Wharam, and P. W. Ladenson, “Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 78, no. 3, pp. 629–634, 1994. View at Publisher · View at Google Scholar · View at Scopus
  29. A. S. Alzahrani, S. Bakheet, M. Al Mandil, A. Al-Hajjaj, A. Almahfouz, and A. Al Haj, “123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 11, pp. 5294–5300, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. D. E. Roos and J. G. Smith, “Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma—a critique,” International Journal of Radiation Oncology Biology Physics, vol. 44, no. 3, pp. 493–495, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. Guidelines for the Management of Thyroid Cancer, B. T. Association, 2nd edition, 2007.
  32. F. Pacini, M. Schlumberger, H. Dralle et al., “European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium,” European Journal of Endocrinology, vol. 154, no. 6, pp. 787–803, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. Thyroid Carcinoma, vol. 2012, N. C. C. Network, 2012.
  34. C. Bal, A. K. Padhy, S. Jana, G. S. Pant, and A. K. Basu, “Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma,” Cancer, vol. 77, no. 12, pp. 2574–2580, 1996. View at Google Scholar · View at Scopus
  35. C. S. Bal, A. Kumar, and G. S. Pant, “Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 4, pp. 1666–1673, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Gawkowska-Suwińska, M. Turska, J. Roskosz et al., “Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer,” Wiadomości Lekarskie, vol. 54, supplement 1, pp. 278–288, 2001. View at Google Scholar · View at Scopus
  37. F. A. Verburg, B. de Keizer, C. J. M. Lips, P. M. J. Zelissen, and J. M. H. de Klerk, “Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients,” European Journal of Endocrinology, vol. 152, no. 1, pp. 33–37, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. P. W. Ladenson, L. E. Braverman, E. L. Mazzaferri et al., “Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma,” New England Journal of Medicine, vol. 337, no. 13, pp. 888–896, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. R. J. Robbins, R. M. Tuttle, R. N. Sharaf et al., “Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 2, pp. 619–625, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Remy, I. Borget, S. Leboulleux et al., “131I effective half-life and dosimetry in thyroid cancer patients,” Journal of Nuclear Medicine, vol. 49, no. 9, pp. 1445–1450, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Pacini, R. Lari, and S. Mazzeo, “Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer,” Clinical Endocrinology, vol. 23, no. 4, pp. 405–411, 1985. View at Google Scholar · View at Scopus
  42. C. P. Barsano, C. Skosey, L. J. DeGroot, and S. Refetoff, “Serum thyroglobulin in the management of patients with thyroid cancer,” Archives of Internal Medicine, vol. 142, no. 4, pp. 763–767, 1982. View at Publisher · View at Google Scholar · View at Scopus
  43. P. W. Grigsby, K. Baglan, and B. A. Siegel, “Surveillance of patients to detect recurrent thyroid carcinoma,” Cancer, vol. 85, no. 4, pp. 945–951, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. A. F. Cailleux, E. Baudin, J. P. Travagli, M. Ricard, and M. Schlumberger, “Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 1, pp. 175–178, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Pacini, M. Capezzone, R. Elisei, C. Ceccarelli, D. Taddei, and A. Pinchera, “Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 4, pp. 1499–1501, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Schlumberger, B. Catargi, I. Borget et al., “Strategies of radioiodine ablation in patients with low-risk thyroid cancer,” New England Journal of Medicine, vol. 366, no. 18, pp. 1663–1673, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. J. C. Sisson, J. Freitas, I. R. McDougall et al., “Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the american thyroid association,” Thyroid, vol. 21, no. 4, pp. 335–346, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. N. G. Iyer, L. G. T. Morris, R. M. Tuttle, A. R. Shaha, and I. Ganly, “Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy,” Cancer, vol. 117, pp. 4439–4446, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. A. P. Brown, J. Chen, Y. J. Hitchcock, A. Szabo, D. C. Shrieve, and J. D. Tward, “The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 2, pp. 504–515, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Rubino, F. De Vathaire, M. E. Dottorini et al., “Second primary malignancies in thyroid cancer patients,” British Journal of Cancer, vol. 89, no. 9, pp. 1638–1644, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. T. C. Sandeep, M. W. J. Strachan, R. M. Reynolds et al., “Second primary cancers in thyroid cancer patients: a multinational record linkage study,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 5, pp. 1819–1825, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Bhattacharyya and W. Chien, “Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma,” Annals of Otology, Rhinology and Laryngology, vol. 115, no. 8, pp. 607–610, 2006. View at Google Scholar · View at Scopus
  53. R. B. T. Verkooijen, J. W. A. Smit, J. A. Romijn, and M. P. M. Stokkel, “The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer,” European Journal of Endocrinology, vol. 155, no. 6, pp. 801–806, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. B. H.-H. Lang, I. O. L. Wong, K. P. Wong, B. J. Cowling, and K.-Y. Wan, “Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy,” Surgery, vol. 151, no. 6, pp. 844–850, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Bonnet, D. Hartl, S. Leboulleux et al., “Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 4, pp. 1162–1167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Jonklaas, D. S. Cooper, K. B. Ain et al., “Radioiodine therapy in patients with stage i differentiated thyroid cancer,” Thyroid, vol. 20, no. 12, pp. 1423–1424, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. A. M. Sawka, K. Thephamongkhol, M. Brouwers, L. Thabane, G. Browman, and H. C. Gerstein, “A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 8, pp. 3668–3676, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. E. K. Alexander and P. R. Larsen, “Radioiodine for thyroid cancer—is less more?” New England Journal of Medicine, vol. 366, no. 18, pp. 1732–1733, 2012. View at Publisher · View at Google Scholar · View at Scopus